RxDoctor Payments Data

Hanna Redd, PA

Physician Assistant · Kansas City, MONPI 1831651611

Payments from drug & device makers

$884in general payments, 2019–2025

Across 37 payments — averaging $23.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axogen$170
  • Johnson & Johnson$135
  • Bristol Myers Squibb$129
  • Sanofi$67
  • Incyte Corporation$51
  • AstraZeneca$43
  • plus $289 from 13 others

What the payments were for

  • Food & beverage$79590%
  • Education$8910%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$884 in reported general payments places this provider in the 70th percentile of 1,380 physician assistant providers in Missouri.

See all physician assistant providers in Missouri

Medicare billing

Part B allowed, 2024
$24,230
Medicare patients
156
Services billed
265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide28$551,545
Lenalidomide24$344,750
ImbruvicaIbrutinib12$181,666
XareltoRivaroxaban21$17,980
EliquisApixaban13$10,800
Acyclovir73$1,087
Hydroxyurea36$414
Ondansetron Hcl15$126
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim40$122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$129$551,54528 claims
Johnson & JohnsonXarelto$135$17,98021 claims
PfizerEliquis$15$10,80013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,380 physician assistant providers in Missouri.

Other physician assistant in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →